Last week, New York-based ProteoMetrics said it is in acquisition talks with Genomic Solutions of Ann Arbor, Mich.
As part of a five-year deal to co-develop and market a new proteomics software product, Genomic Solutions has gained the right of first refusal to acquire ProteoMetrics for a period of 24 months.
Weve been on the market to be invested in or acquired for the last three or four months, said ProteoMetrics spokesman Gould Porter. Were looking for strategic partnerships or alliances but weve also spoken about mergers or acquisitions.
The two companies are working on a software product that will integrate Genomic Solutions Investigator Protein Warehouse data integration software with ProteoMetrics Radars mass spectrometry analysis system.
Under the terms of the agreement, Genomic Solutions will also market ProteoMetrics Knexus, Profound, and Sonar MS/MS software products.
This is the second bioinformatics partnership Genomic Solutions has entered recently. On July 19, the company said it was working with Atlanta-based NuTec Sciences to develop microarray analysis software for its GeneTac microarray system.
Kathleen Murphy, Genomic Solutions vice president of corporate communications, said that the companys software development staff of approximately 10 people focuses on supporting its Investigator Proteomic System, which includes 2D electrophoresis, imaging, and image analysis.
While Genomic Solutions doesnt offer mass spectrometry capability, its systems integrate with mass spec systems from other major vendors, which makes the partnership a great fit, according to Doug Lockyer, co-CEO of ProteoMetrics. By integrating experimental data from instrument manufacturers such as Genomic Solutions with mass spectra from diverse sources analyzed and archived with our intelligence platforms, we can deliver a greater volume of valuable proteomic and genomic knowledge, more rapidly, Lockyer said.
The co-developed software, which will be bundled with Genomic Solutions proteomics tools, is expected to be available by the end of the year.
Porter said that an acquisition wouldnt impact ProteoMetrics current partnerships. An acquirer would not take over the day-to-day management of the company, Porter said. Rather, it would be an investment to increase their capital in the long run.